Replies to post #1068 on ImmunoGen Inc (IMGN)

[vinmantoo]

Vinmantoo, we're in much the same position, but I'm far from thrilled about the price IMGN is taking. I understand that ABBV's revenue estimate for Elahere alone is $2 billion a year, that alone should justify a $20 billion buyout with a P/E of only 10 and it could very well be 20 or more over the years. In the clinic they're already getting what should be the second generation of Elahere, an even more effective drug which should have a broader label. Their drug, Pivek, for BPDCN ought to be a sure approval for it, whether it's benefit in leukemia is that great, or not. It may, or may not be a blockbuster, depending on the outcome with leukemia, but it's a miracle worker for BPDCN.

Gary, you are preaching to the choir. While I am disappointed the buyout price isn't higher, I am very grateful for this windfall, at least for me. I doubt what individual shareholders say matters with regards to approving the buyout as the institutional shareholders hold all the cards. They almost certainly prefer the sure quick payout rather than a rejection in the hopes for a bigger one a year or two later.

Good luck with NWBO. I have no idea what they are about.